Expert Consultations: Real-World Answers

Assessment and Management of First Episode of Psychosis – Interview

Published on November 1, 2022 Certification expiration date: November 1, 2028

Guest

Radwa Hanafy

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

For patients with first-episode psychosis, consider individual patient goals and align treatment strategies accordingly.
Monitor all patients for weight gain and adverse metabolic parameters, regardless of what antipsychotic is being taken.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Stephen Marder, M.D., who is a professor of psychiatry at the Semel Institute at University of California, Los Angeles. He is also the Director of the Mental Illness Research, Education, and Clinical Center in Los Angeles. In this interview, we will discuss the assessment and management of the first episode of psychosis.

Radwa Hanafy, M.D.: Dr. Marder, I really enjoyed watching your lecture about such an interesting topic, especially as the first episode of psychosis is a critical period in

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Articulate the importance of early identification and management of the clinical high-risk state for psychosis (CHR-P) and first-episode psychosis.
Summarize treatment options for first-episode psychosis based on current literature.
Identify techniques that promote adherence to medications among patients with first-episode psychosis.

Original Release Date: November 1, 2022

Review and Re-release Date: November 1, 2025

Expiration Date: November 1, 2028

Expert: Stephen Marder, M.D.

Medical Editors: Radwa Hanafy, M.D., Melissa Mariano, M.D.

Relevant Financial Disclosures:

Stephen R Marder declares the following interests:

– Merck: consultant

– Sunovion: consultant

– Boehringer-Ingelheim: consultant

– Newron: consultant

– Boehringer-Ingelheim: research funding

– Roche: consultant

All of the relevant financial relationships listed above have been mitigated by Medical Academy and the Psychopharmacology Institute.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Stephen R. Marder, M.D.